Definium Therapeutics (NASDAQ: DFTX) net income
Definium Therapeutics reported a net loss of $183.8m for fiscal 2025; in fiscal 2024 it reported a net loss of $108.7m. Earnings per share were −$2.06.
Definium Therapeutics's best year of the last 6 was fiscal 2020. It reported a loss in 6 of those 6 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$183.8m | — | — | −$2.06 |
| 2024 | −$108.7m | — | — | −$1.54 |
| 2023 | −$95.7m | — | — | −$2.44 |
| 2022 | −$56.8m | — | — | −$1.84 |
| 2021 | −$93.0m | — | — | −$3.40 |
| 2020 | −$33.9m | — | — | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Definium Therapeutics net income compared with its sector
By net income for its latest fiscal year, Definium Therapeutics ranks 402nd of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 400th | Zai Lab | −$175.5m | −38.1% |
| 401st | Celcuity | −$177.0m | — |
| 402nd | Definium Therapeutics | −$183.8m | — |
| 403rd | Glaukos | −$187.7m | −37.0% |
| 404th | Allogene Therapeutics | −$190.9m | −7,341.8% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Definium Therapeutics
- How much did Definium Therapeutics earn in fiscal 2025?
- Definium Therapeutics reported a net loss of $183.8m for fiscal 2025. In fiscal 2024 it reported a net loss of $108.7m.
- What are the earnings per share of Definium Therapeutics?
- They were −$2.06 in fiscal 2025, compared with −$1.54 in fiscal 2024.
- Where does Definium Therapeutics rank in its sector by net income?
- It ranks 402nd of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Definium Therapeutics come from?
- From the annual report (Form 10-K) that Definium Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Definium Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Definium Therapeutics: the Definium Therapeutics page · annual accounts · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.